Neuroprotection conferred by post-ischemia ethanol therapy in experimental stroke: an inhibitory effect on hyperglycolysis and NADPH oxidase activation.

Ethanol provides neuroprotection following ischemia/reperfusion. This study assessed ethanol's effect on hyperglycolysis and NADPH oxidase (NOX) activation. Adult, male Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) for 2 h. Three sets of experiments were conducted to determine ethanol's effect on (i) conferring neuroprotection by measuring infarct volume and neurological deficits 24 h post reperfusion; (ii) cerebral glucose metabolism and lactic acidosis by measuring brain and blood glucose concentrations and protein expression of glucose transporter 1 and 3 (GLUT1, GLUT3), phosphofructokinase (PFK), as well as lactic acidosis by measuring lactate dehydrogenase (LDH), and lactate; and (iii) nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) activation by detecting enzymatic activity and subunit expression at 3 h after reperfusion. When administered upon reperfusion, ethanol (1.5 g/kg) reduced infarct volume by 40% (p < 0.01) and neurological deficits by 48% at 24 h post reperfusion while reducing (p < 0.01) elevations in glycolytic protein expression and lactate levels during early reperfusion (3 h). Ethanol increased the reductions in cerebral glucose concentration at 3 h post reperfusion by 64% (p < 0.01) while enhancing (p < 0.01) post stroke blood glucose concentration, suggesting a reduced cellular glucose uptake and utilization. Ethanol decreased (p < 0.01) stroke-induced NOX activation by reducing enzymatic activity and gp91(phox) expression by 45% and 38%, respectively. Post-ischemia ethanol treatment exerts neuroprotection through attenuation of hyperglycolysis and associated NOX activation. Because of the lack of associated hypoglycemia and selectivity toward decreasing cerebral metabolism, further investigation of ethanol's use as a post-stroke therapy, especially in the context of hyperglycemia, seems warranted.
AuthorsRyan Kochanski, Changya Peng, Tetsuhiro Higashida, Xiaokun Geng, Maik Hüttemann, Murali Guthikonda, Yuchuan Ding
JournalJournal of neurochemistry (J Neurochem) Vol. 126 Issue 1 Pg. 113-21 (Jul 2013) ISSN: 1471-4159 [Electronic] England
PMID23350720 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013 International Society for Neurochemistry.
Chemical References
  • Blood Glucose
  • Central Nervous System Depressants
  • Glucose Transporter Type 1
  • Glucose Transporter Type 3
  • Neuroprotective Agents
  • Slc2a1 protein, rat
  • Slc2a3 protein, rat
  • Lactic Acid
  • Ethanol
  • Adenosine Diphosphate
  • Adenosine Triphosphate
  • L-Lactate Dehydrogenase
  • NADPH Oxidase
  • Phosphofructokinases
  • Adenosine Diphosphate (metabolism)
  • Adenosine Triphosphate (metabolism)
  • Animals
  • Behavior, Animal (drug effects)
  • Blood Glucose (metabolism)
  • Brain Chemistry (physiology)
  • Brain Ischemia (drug therapy, pathology, psychology)
  • Central Nervous System Depressants (therapeutic use)
  • Cerebral Infarction (drug therapy, pathology)
  • Ethanol (therapeutic use)
  • Glucose Transporter Type 1 (metabolism)
  • Glucose Transporter Type 3 (metabolism)
  • Glycolysis (drug effects)
  • L-Lactate Dehydrogenase (metabolism)
  • Lactic Acid (metabolism)
  • Male
  • NADPH Oxidase (metabolism)
  • Neuroprotective Agents
  • Phosphofructokinases (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Stroke (drug therapy, pathology, psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: